As AbbVie Ireland’s new general manager, Dana Kendall will oversee the company’s commercial business in the country.

In the most recent trading session, AbbVie (ABBV) closed at $171.63, indicating a -1% shift from the previous trading day.

CTLA-4 inhibitors are a well-established market in cancer care, and they are expected to grow significantly in the coming ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

AbbVie is a strong investment opportunity with growth potential, dividend income, and a diverse drug portfolio. Find out why ...

Breast Reconstruction Market Outlook to 2031The global breast reconstruction market was valued at US$ 1.4 billion in 2021 and is projected to grow at a CAGR of 5.3% from 2022 to 2031, reaching more ...

AbbVie ABBV announced that it has entered into a definitive agreement to acquire privately held biotech, Nimble Therapeutics.

But making AbbVie an even more interesting and timely stock to look at, is the fact that in trading on Monday, shares of ABBV ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial ...